AB0812-PC Clinical and epidemiological characteristics of women with breast cancer and aromatase inhibitors treatment who presented hip fracture between 2008-2010

Background The main source of estrogen is produced in peripheral tissues in post-menopausal women. Due to this, lowering estrogen production at peripheral tissues with aromatase inhibitors might be an additional risk factor for osteoporosis and hip fracture. Objectives Our aim was to analyzethe clinical and epidemiological characteristics of women who had a hip fracture and had been diagnosed as having breast cancer and treated with IA Methods We conducted a retrospective study of the case records of all adults women diagnosed with hip fracture and IA treatment for breast cancer from January 2008 through December 2010. The Hospital Universitario Lucus Augusti is the only referral center for our population. Statistical analyses were performed using SPSS. Results Thirteen women who had suffered breast cancer and IA treatment presented hip fracture during the period 2008-2010. From all hip fractures found, 7 were trochanteric, 3 subtrochanteric and 3 had occurred in femoral neck. The median age at the time of fracture was 83 years. All fractures require hospitalization and surgery. The median age at the time of breast cancer diagnosis was 72 years. All patients were treated with third-generation IA and none had been previously diagnosed as having osteoporosis. Five patients (38.4%) received anti-osteoporotic treatment after hip fracture. Conclusions Hip fractures occur in those patients with breast cancer and treatment with IA when they have diagnosed in an elderly age (median age 72). In these patients, a better physician awareness looking for risk factor for osteoporosis, especially in elderly people could decrease the number of hip fractures. Treatment after hip fracture should be required. References Disclosure of Interest None Declared